KAKEN PHARMACEUTIAL CO., LTD. (4521) Stock Price

Kaken Pharmaceutical has two main business segments: pharmaceuticals and real estate. In the pharmaceuticals segment, the company manufactures and sells pharmaceutical products, medical devices, and agricultural chemicals. This segment involves Kaken Pharmaceutical itself, as well as Kaken Pharma Co., Ltd., Arsam Co., Ltd., KAKEN INVESTMENTS INC., and Ardi Co.

The real estate segment primarily handles property leasing operations. This business is managed directly by Kaken Pharmaceutical. These business segments align with the segment information in Kaken Pharmaceutical's consolidated financial statements. On March 26, 2025, Kaken Pharmaceutical acquired 100% of Ardi Co.'s shares, making it a consolidated subsidiary.

Kaken Pharmaceutical is guided by a corporate philosophy of improving patients' quality of life through the provision of medicines. The company prioritizes the creation and supply of pharmaceuticals that meet the needs of patients and healthcare professionals, with a fundamental commitment to fulfilling social responsibility. Additionally, the company aims to become an organization its employees can take pride in while maximizing corporate value.

Within the rapidly evolving pharmaceutical industry, Kaken Pharmaceutical faces demands for efficient new drug development and stable supply. In particular, as the need for treatments addressing rare and intractable diseases grows, rising research and development costs present a significant challenge. The company is strengthening organizational capability through employee development and pursuing active investment in research and development.

Kaken Pharmaceutical's medium-term management strategy is based on a ten-year plan through fiscal 2031. This plan aims to contribute to extending healthy life expectancy by rapidly developing and delivering innovative new drugs. The company also intends to expand globally, with a focus on dermatology and orthopedic fields.

The company's growth strategy is built on three transformations: research and development, international expansion, and management foundation strengthening. In research and development, the company is leveraging its own research capabilities and expanding into new therapeutic areas. In international expansion, the company is strengthening its direct sales operations in the U.S. market, centered on Ardea Biosciences.

Kaken Pharmaceutical targets consolidated net sales of 100 billion yen, consolidated operating profit of 28.5 billion yen, and consolidated ROE of 10.0% or higher by fiscal 2031. To achieve these goals, the company is increasing strategic investments and enhancing shareholder returns. Through these initiatives, the company is pursuing sustainable growth.